Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01029054 · ClinicalTrials.gov registry record · Phase 1
Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma
A Phase 1 study, sponsored by University of Michigan Rogel Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 53
- Enrollment target
NCT01029054 is a Phase 1 study that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 53 participants.
The verdict
NCT01029054, a Phase 1 study, has completed, sponsored by University of Michigan Rogel Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 53 participants
- Enrollment target
Study Summary
This study is designed to evaluate the safety and to determine the maximum tolerated dose of carfilzomib + lenalidomide in combination with dexamethasone in newly diagnosed Multiple Myeloma patients who have not received treatment.
Interventions
- DRUG carfilzomib, lenalidomide plus dexamethasone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2009-09 |
| Est. Completion | 2015-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01029054
The ClinicalTrials.gov registry entry for NCT01029054 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which carfilzomib, lenalidomide plus dexamethasone is the first listed.
NCT01029054 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01029054 about?
NCT01029054 is a clinical study titled "Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma". This study is designed to evaluate the safety and to determine the maximum tolerated dose of carfilzomib + lenalidomide in combination with dexamethasone in newly diagnosed Multiple Myeloma patients who have not received treatment.
What is the current status of trial NCT01029054?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 53 participants. The study started on 2009-09. Estimated completion is 2015-07.
What interventions are being tested in trial NCT01029054?
The interventions under investigation include: carfilzomib, lenalidomide plus dexamethasone (DRUG).
Who is sponsoring clinical trial NCT01029054?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.